MedTrace Logo

Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease

NCT04509271 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2021-09-27

No results posted yet for this study

Summary

The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%. Peripheral Blood biomarkers is the key and difficult points in AD research. Except expensive brain β amyloid plaque imaging, few breakthroughs of early diagnosis technology of MCI due to AD can be made to facilitate clinical application. Even Tau-181 and Tau-217 were reported in this year on Lancet neurology and JAMA. We also need to study on the biomarkers upstream of pathological changes about senile plaque. The purpose of this program is to study the reliability and validity of plasma miRNAs for early diagnosis of MCI due to AD and other dementia such as DLB and FTLD. The clinical diagnosis of AD and MCI due to AD are according to the National Institute of Aging and the Alzheimer's Disease Association (NIA-AA) diagnostic criteria in 2011. Plaque imaging is used to be golden criteria for the diagnosis of AD and MCI due to AD.

Conditions

  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

MicRNAs battery kits

Novel peripheral blood diagnostic biomarker for MCI due to AD.

Sponsors & Collaborators

  • Shanghai Mental Health Center

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-01-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04509271 on ClinicalTrials.gov